Skip to main content
OpenTrials

Clinical trial condition

Hormone Receptor Positive Breast Carcinoma

Explore clinical trials studying Hormone Receptor Positive Breast Carcinoma. Study availability and eligibility vary by location and protocol.

21 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Hormone Receptor Positive Breast Carcinoma trial results

Completed

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

NCT04505826

Conditions
HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Locations
  • UCLA Hematology/Oncology Los Angeles, California, United States
  • University of Colorado Aurora, Colorado, United States
  • University of Miami, Sylvester Comprehensive Cancer Center Deerfield Beach, Florida, United States
  • Advent Health Orlando, Florida, United States
View all 19 locations
View Trial Details
Completed

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

NCT05173103

Conditions
Advanced Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Locations
  • Clinica Oncologica Aou Ospedali Riuniti Ancona, Italy
  • Ospedale Cardinal Massaia Asti Asti, Italy
  • Ospedale San Martino Belluno, Italy
  • OSPEDALE Sacro Cuore di Gesù - Fatebenefratelli Benevento, Italy
View all 29 locations
View Trial Details
Completed

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +22 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • California Cancer Care Associates for Research & Excellence, Inc. San Marcos, California, United States
  • St. Joseph Heritage Healthcare Santa Rosa, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
View Trial Details
Active, Not Recruiting

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117

Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Breast Diseases, Breast Neoplasms, +7 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 104 locations
View Trial Details
Active, Not Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979

Conditions
HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, PIK3CA Mutant Metastatic Breast Cancer
Locations
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
  • Penn State Cancer Institute Hershey, Pennsylvania, United States
  • University of Wisconsin Madison, Wisconsin, United States
View Trial Details
Active, Not Recruiting

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

NCT04379570

Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, +6 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Arizona Center for Cancer Care - Gilbert Gilbert, Arizona, United States
  • Arizona Center for Cancer Care-Peoria Peoria, Arizona, United States
View all 526 locations
View Trial Details

Related conditions